ImmunoTargets and Therapy (Apr 2024)
Clinical Significance of Uncommon, Non-Clinical, and Novel Autoantibodies
Abstract
Michael R Shurin, Sarah E Wheeler Division of Clinical Immunopathology, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USACorrespondence: Michael R Shurin, UPMC Immunopathology, 3477 Euler Way, CLB, Room 4024, Pittsburgh, PA, 15213, USA, Email [email protected]: Autoantibodies are a common mark of autoimmune reaction and their identification in the patients’ serum, cerebrospinal fluid, or tissues is generally believed to represent diagnostic or prognostic biomarkers of autoimmune diseases or autoinflammatory conditions. Traditionally, autoantibody testing is an important part of the clinical examination of suspected patients, and in the absence of reliable T cell tests, characterization of autoantibody responses might be suitable in finding causes of specific autoimmune responses, their strength, and sometimes commencement of autoimmune disease. Autoantibodies are also useful for prognostic stratification in clinically diverse groups of patients if checked repeatedly. Antibody discoveries are continuing, with important consequences for verifying autoimmune mechanisms, diagnostic feasibility, and clinical management. Adding newly identified autoantibody-autoantigen pairs to common clinical laboratory panels should help upgrade and harmonize the identification of systemic autoimmune rheumatic disorders and other autoimmune conditions. Herein, we aim to summarize our current knowledge of uncommon and novel autoantibodies in the context of discussing their validation, diagnostic practicability, and clinical relevance. The regular updates within the field are important and well justified.Keywords: autoimmune diseases, autoantibodies, autoantigen, immunological disorders
